Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab

Leukemia and Lymphoma

Volumn 47, Issue 9, 2006, Pages 1830-1840

  Czuczman, M S ^a   Grillo Lopez A J ^b   Alkuzweny, B ^c   Weaver, R ^c   Larocca, A ^c   Mclaughlin, P ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Neoplastic and Autoimmune Diseases Research Institute   (United States)

^c BIOGEN   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Follicular lymphoma; Non Hodgkin's lymphoma; Prognostic factors; Rituximab

Indexed keywords

ACEPROMAZINE; ANTHRACYCLINE; BETA 2 MICROGLOBULIN; CD3 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LACTATE DEHYDROGENASE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33750481565     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600709523     Document Type: Article

References (42)

1. Rosenberg, S and Berard, C and Brown, B, Jr and Burke, J and Dorfman, R and Glatstein, E and (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project Cancer, 49, pp. 2112-2135.
2. Horning, S. (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas Semin Oncol, 20(5 Suppl 5), pp. 75-88.
3. Solal-Celigny, P and Roy, P and Colombat, P and White, J and Armitage, J and Arranz-Saez, R and (2004) Follicular lymphoma international prognostic index Blood, 104, pp. 1258-1265.
4. Armitage, J and Berg, A and Purtilo, D. (1993) Adult non-Hodgkin's lymphomas. In Hematology: Clinical and Laboratory Practice. (pp. 875-893). St Louis MO: CV Mosby Company.
5. Gallagher, C and Gregory, W and Jones, A and Stansfeld, A and Richards, M and Dhaliwal, H and (1986) Follicular lymphoma: Prognostic factors for response and survival J Clin Oncol, 4, pp. 1470-1480.
6. Esteve, J and López-Guillermo, A and Martínez-Francés, A and Bosch, F and Terol, M and Campo, E and (1995) Presenting features, natural history, and prognostic factors in localized non-Hodgkin's lymphomas: Analysis of 117 cases from a single institution Eur J Haematol, 55, pp. 217-222.
7. Bastion, Y and Berger, F and Bryon, P and Felman, P and Ffrench, M and Coiffier, B. (1991) Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 years Ann Oncol, 2(Suppl 2), pp. 123-129.
8. Romaguera, J and McLaughlin, P and North, L and Dixon, D and Silvermintz, K and Garnsey, L and (1991) Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model J Clin Oncol, 9, pp. 762-769.
9. López-Guillermo, A and Cabanillas, F and McLaughlin, P and Smith, T and Hagemeister, F and Rodriquez, M and (1998) The clinical significance of molecular response in indolent follicular lymphomas Blood, 91, pp. 2955-2960.
10. Montoto, S and López-Guillermo, A and Ferrer, A and Camós, M and Alvarez-Larrán, A and Bosch, F and (2002) Survival after progression in patients with follicular lymphoma: Analysis of prognostic factors Ann Oncol, 13, pp. 523-530.
11. Johnson, P and Rohatiner, A and Whelan, J and Price, C and Love, S and Lim, J and (1995) Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center J Clin Oncol, 13, pp. 140-147.
12. Shipp, M and Harrington, D and Anderson, J and Armitage, J and Bonadonna, G and Brittinger, G and (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med, 329, pp. 987-994.
13. López-Guillermo, A and Montserrat, E and Bosch, F and Terol, M and Campo, E and Rozman, C. (1994) Applicability of the International Index for Aggressive Lymphomas to patients with low-grade lymphoma J Clin Oncol, 12, pp. 1343-1348.
14. Foussard, C and Desablens, B and Sensebe, L and François, S and Milpied, N and Deconinck, E and (1997) Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicablity to stage III-IV patients Ann Oncol, 8(Suppl 1), pp. 49-52.
15. Reff, M and Carner, K and Chambers, K and Chinn, P and Leonard, J and Raab, R and (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood, 83, pp. 435-445.
16. Grillo-López, A and White, C and Varns, C and Shen, D and Wei, A and McClure, A and (1999) Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma Semin Oncol, 26(5 Suppl 14), pp. 66-73.
17. Piro, L and White, C and Grillo-López, A and Janakiraman, N and Saven, A and Beck, T and (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Ann Oncol, 10, pp. 655-661.
18. Davis, T and Grillo-López, A and White, C and McLaughlin, P and Czuczman, M and Link, B and (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment J Clin Oncol, 18, pp. 3135-3143.
19. Davis, T and White, C and Grillo-López, A and Velásquez, W and Link, B and Maloney, D and (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a Phase II trial of rituximab J Clin Oncol, 17, pp. 1851-1857.
20. Czuczman, M and Weaver, R and Alkuzweny, B and Berlfein, J and Grillo-Lopez, A. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up J Clin Oncol, 22, pp. 4711-4716.
21. Vose, J and Link, B and Grossbard, M and Czuczman, M and Grillo-López, A and Gilman, P and (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol, 19, pp. 389-397.
22. Marcus, R and Imrie, K and Belch, A and Cunningham, D and Flores, E and Catalano, J and (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma Blood, 105, pp. 1417-1423.
23. McLaughlin, P and Grillo-López, A and White, C and Czuczman, M and Maloney, D and Alkuzweny, B and (1999) Prognostic factors for non-Hodgkin's lymphoma (NHL) patients treated with chemotherapy (CRX) may not predict response duration in patients treated with immunotherapy: Rituximab experience Am Assoc Canc Res, 40, pp. 718(#4746).
24. McLaughlin, P and Grillo-Loacute;pez, A and Link, B and Levy, R and Czuczman, M and Williams, M and (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program J Clin Oncol, 16, pp. 2825-2833.
25. Grillo-López, A and Lee, D and Alkuzweny, B and Shen, D and Nasizadeh, H. (2000) Clinical activity of rituximab in patients who have relapsed following ABMT Proc Am Soc Clin Oncol, 19, pp. 23a(#18).
26. Grillo-López, A. (2000) Rituximab: An insider's historical perspective Semin Oncol, 27(6 Suppl 12), pp. 9-16.
27. Harris, N and Jaffe, E and Stein, H and Banks, P and Chan, J and Cleary, M and (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group Blood, 84, pp. 1361-1392.
28. Cheson, B and Horning, S and Coiffier, B and Shipp, M and Fisher, R and Connors, J and (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma J Clin Oncol, 17, pp. 1244-1253.
29. Grillo-López, A. (2003) Rituximab (Rituxan®/MabThera®): the first decade (1993-2003) Expert Rev Anticancer Ther, 3, pp. 767-779.
30. Grillo-López, A and Cheson, B and Horning, S and Peterson, B and Carter, W and Varns, C and (2000) Response criteria for NHL: Importance of 'normal' lymph node size and correlations with response rates Ann Oncol, 11, pp. 399-408.
31. SAS. (1990) SAS/STAT User's Guide, version 6, 4th edn. Cary NC: SAS Institute, Inc.
32. Kaplan, E and Meier, P. (1958) Nonparametric estimation for incomplete observations J Am Stat Assoc, 53, pp. 456-481.
33. Hermans, J and Krol, A and van Groningen, K and Kluin, P and Kluin-Nelemans, J and Kramer, M. (1995) International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades Blood, 86, pp. 1460-1463.
34. Bastion, Y and Coiffier, B. (1994) Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients? J Clin Oncol, 12, pp. 1340-1342.
35. Foran, J and Cunningham, D and Coiffier, B and Solal-Celigny, P and Reyes, F and Ghielmini, M and (2000) Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response Ann Oncol, 11(Suppl 1), pp. S117-S121.
36. Igarashi, T and Kobayashi, Y and Ogura, M and Kinoshita, T and Ohtsu, T and Sasaki, Y and (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study Ann Oncol, 13, pp. 928-943.
37. Yunis, J and Oken, M and Kaplan, M and Ensrud, K and Howe, R and Theologides, A. (1982) Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma N Engl J Med, 307, pp. 1231-1236.
38. Czuczman, M and Grillo-López, A and McLaughlin, P and White, C and Saleh, M and Gordon, L and (2001) Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy Ann Oncol, 12, pp. 109-114.
39. Mangel, J and Buckstein, R and Imrie, K and Spaner, D and Crump, M and Tompkins, K and (2002) Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma Semin Oncol, 29(1 Suppl 2), pp. 56-69.
40. Colombat, P and Salles, G and Brousse, N and Eftekhari, P and Soubeyran, P and Delwail, V and (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation Blood, 97, pp. 101-106.
41. Ferraris, A and Giuntini, P and Gaetana, G. (1979) Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas Blood, 54, pp. 928-932.
42. Grillo-López, A. (2002) A model for the breadth and depth of clinical effect observed with rituximab and Zevalin in NHL patients Blood, 100, pp. 310b.